We hereby submit Audited Financial Results for Q4 & FY2026.

Revenue growth above 20%Profit growth above 25%EBITDA margin compressionDebt to equity above the thresholdResults View source PDF Explain this filing

YATHARTH · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.1%Reaction day

₹860.20

prior close

₹834.55

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.6%-6.7% vs market

Hospital peers, median of 23sector+0.4%-5.6% vs sector

On the reaction day the stock moved 6.7 pts less than Nifty Microcap 250 and 5.6 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.8

10m

-2.3

15m

-1.8

30m

-2.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.1+1.6-6.7+0.4-5.6

Next day

-4.8+2.3-7.1+0.3-5.1

-5.3+2.3-7.5+0.0-5.3

-8.2+1.6-9.8-0.3-7.8

-8.2+0.5-8.7-0.9-7.2

-5.4+1.6-7.0-1.0-4.4

-5.8+2.7-8.6-0.4-5.4

15d

-3.9+5.4-9.2+0.7-4.5

-2.8+7.3-10.0+2.3-5.1

-1.8+8.6-10.3+5.7-7.4

+7.6+13.0-5.4+4.0+3.6

UpDownMarket · Nifty Microcap 250Sector · Hospital peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Yatharth Hospital reported strong FY2026 results with standalone revenue growing 30% to ₹5,919 million and consolidated revenue up 36% to ₹12,072 million. Consolidated profit after tax jumped 30% to ₹1,703 million, translating to EPS of ₹18.20 versus ₹14.72 in FY2025. The company expanded its hospital network during the year—acquiring a 300-bed facility in Delhi's Model Town (operational from July 2025), a 400-bed hospital in Faridabad (September 2025), and a 150-bed Shantived hospital in Agra (February 2026). Finance costs surged significantly (standalone: ₹57 million vs ₹6 million last year) due to increased borrowings for acquisitions. The statutory auditor MSKA & Associates issued an unmodified opinion, and no going concern or qualified opinion issues were raised.

Likely market impact

The results demonstrate robust growth driven by network expansion and acquisitions, though the sharp increase in finance costs warrants monitoring. The stock's EPS improvement and strong revenue trajectory are positive signals for shareholders, but rising debt levels to fund acquisitions may concern some investors.